These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 16312526)

  • 21. Pharmacokinetics of maribavir, a novel oral anticytomegalovirus agent, in subjects with varying degrees of renal impairment.
    Swan SK; Smith WB; Marbury TC; Schumacher M; Dougherty C; Mico BA; Villano SA
    J Clin Pharmacol; 2007 Feb; 47(2):209-17. PubMed ID: 17244772
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Steady-state intravenous pharmacokinetics of pirenzepine in patients with hepatic insufficiency and combined renal- and hepatic insufficiency.
    Krakamp B; Tanswell P; Leidig P; Vogel H; Schmitz R; Bozler G
    Eur J Clin Pharmacol; 1989; 36(1):71-3. PubMed ID: 2917592
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics of dalbavancin in patients with renal or hepatic impairment.
    Marbury T; Dowell JA; Seltzer E; Buckwalter M
    J Clin Pharmacol; 2009 Apr; 49(4):465-76. PubMed ID: 19318696
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Pharmacokinetics in renal insufficiency].
    Arancibia A; Ruiz I
    Rev Med Chil; 1984 Mar; 112(3):267-75. PubMed ID: 6473969
    [No Abstract]   [Full Text] [Related]  

  • 25. Antimicrobials in renal impairment.
    Lefrock JL; Smith BR
    Am Fam Physician; 1982 Jun; 25(6):201-5. PubMed ID: 7081009
    [No Abstract]   [Full Text] [Related]  

  • 26. [How to evaluate hepatic function: pharmacokinetic approach].
    Malè PJ
    Rev Med Suisse Romande; 1985 Apr; 105(4):313-6. PubMed ID: 4012141
    [No Abstract]   [Full Text] [Related]  

  • 27. Fleroxacin pharmacokinetics in healthy volunteers and impaired renal function.
    Höffler D; Koeppe P; Metz R; Pech M; Sörgel F
    J Chemother; 1989 Jul; 1(4 Suppl):558-60. PubMed ID: 16312531
    [No Abstract]   [Full Text] [Related]  

  • 28. Pharmacokinetics and metabolism of FCE 22101, a new penem antibiotic.
    Jannuzzo MG; Vaiani R; Strolin Benedetti M; Carnovali M; Cassinelli G; Corigli R
    J Chemother; 1989 Jul; 1(4 Suppl):511-2. PubMed ID: 16312508
    [No Abstract]   [Full Text] [Related]  

  • 29. Metronidazole kinetics and liver function in hepatic cirrhosis.
    Kampf D; Borner K; Huber S
    Chemioterapia; 1987 Jun; 6(2 Suppl):311-2. PubMed ID: 3509427
    [No Abstract]   [Full Text] [Related]  

  • 30. [A dosage regimen for epicillin in renal impairment (author's transl)].
    Humair L; Modde H; Kienel G
    Arzneimittelforschung; 1981; 31(4):722-5. PubMed ID: 7195720
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis.
    Chen N; Lau H; Kong L; Kumar G; Zeldis JB; Knight R; Laskin OL
    J Clin Pharmacol; 2007 Dec; 47(12):1466-75. PubMed ID: 17954615
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [An emerging concept: pharmacokinetic changes in antibiotics eliminated by the kidney in liver diseases. Mechanisms].
    Palatini P
    G Ital Chemioter; 1991; 38(1-3):19-21. PubMed ID: 1365588
    [No Abstract]   [Full Text] [Related]  

  • 33. The influence of host factors on drug response. VII. Renal diseases.
    Vesell ES
    Ration Drug Ther; 1981 Nov; 15(11):1-9. PubMed ID: 7345476
    [No Abstract]   [Full Text] [Related]  

  • 34. Pharmacokinetics of enoxacin and its oxometabolite after multiple oral dosing and penetration into prostatic tissue.
    Hamel B; Mottet N; Audran M; Costa P; Bressolle F
    J Antimicrob Chemother; 2000 Dec; 46(6):993-6. PubMed ID: 11102420
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy.
    Perucca E; Cloyd J; Critchley D; Fuseau E
    Epilepsia; 2008 Jul; 49(7):1123-41. PubMed ID: 18503564
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dosage of chemotherapeutic agents in patients with renal disease.
    Dettli L
    Prog Clin Biol Res; 1979; 35():141-6. PubMed ID: 538028
    [No Abstract]   [Full Text] [Related]  

  • 37. Pharmacokinetic study of memantine in healthy and renally impaired subjects.
    Periclou A; Ventura D; Rao N; Abramowitz W
    Clin Pharmacol Ther; 2006 Jan; 79(1):134-43. PubMed ID: 16413248
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics of ciprofloxacin in liver cirrhosis.
    Ruhnke M; Trautmann M; Borner K; Hopfenmüller W
    Chemotherapy; 1990; 36(6):385-91. PubMed ID: 2292201
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Does impairment of renal and hepatic function influence the metabolism of thrombolytics in patients with myocardial infarction?
    Vincze Z; Brugos B
    Pharmazie; 2008 Mar; 63(3):245-6. PubMed ID: 18444516
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High serum concentrations of mezlocillin in a critically ill patient with renal and hepatic dysfunction.
    Cooper BE; Nester TJ; Armstrong DK; Dasta JF
    Clin Pharm; 1986 Sep; 5(9):764-6. PubMed ID: 3757449
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.